{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:05:45Z","timestamp":1793747145396,"version":"4.6.1"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100008770","name":"Anadolu University","doi-asserted-by":"publisher","award":["AUBAP- 2104S015"],"award-info":[{"award-number":["AUBAP- 2104S015"]}],"id":[{"id":"10.13039\/501100008770","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.neuropharm.2025.110454","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T13:45:04Z","timestamp":1743860704000},"page":"110454","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Aripiprazole: The antiallodynic and antihyperalgesic effects in chronic constriction injury-induced neuropathic pain and reserpine-induced fibromyalgia with possible mechanisms"],"prefix":"10.1016","volume":"273","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1254-7612","authenticated-orcid":false,"given":"Yagmur","family":"Okcay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zlem","family":"Ayka\u00e7","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana","family":"Arslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurcan","family":"Bektas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2025.110454_bib1","first-page":"325","article-title":"Progression of fibromyalgia: results from a 2-year observational fibromyalgia and chronic pain study in the US","author":"Adams","year":"2016","journal-title":"J. Pain Res."},{"key":"10.1016\/j.neuropharm.2025.110454_bib2","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ejphar.2015.08.053","article-title":"The antipsychotic aripiprazole induces antinociceptive effects: possible role of peripheral dopamine D2 and serotonin 5-HT1A receptors","volume":"765","author":"Almeida-Santos","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110454_bib3","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejphar.2014.09.004","article-title":"The antipsychotic aripiprazole selectively prevents the stimulant and rewarding effects of morphine in mice","volume":"742","author":"Almeida-Santos","year":"2014","journal-title":"Eur. J. Pharmacol."},{"issue":"7","key":"10.1016\/j.neuropharm.2025.110454_bib4","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1080\/00325481.2017.1336417","article-title":"Challenges of implementing fibromyalgia treatment guidelines in current clinical practice","volume":"129","author":"Arnold","year":"2017","journal-title":"Postgrad. Med. J."},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110454_bib5","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.mayocp.2012.02.010","article-title":"A framework for fibromyalgia management for primary care providers","volume":"87","author":"Arnold","year":"2012","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.neuropharm.2025.110454_bib6","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.brainres.2015.06.043","article-title":"Role of spinal 5-HT5A, and 5-HT1A\/1B\/1D, receptors in neuropathic pain induced by spinal nerve ligation in rats","volume":"1622","author":"Avila-Rojas","year":"2015","journal-title":"Brain Res."},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110454_bib7","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/ana.24017","article-title":"Peripheral input and its importance for central sensitization","volume":"74","author":"Baron","year":"2013","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2025.110454_bib8","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0304-3959(88)90209-6","article-title":"A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man","volume":"33","author":"Bennett","year":"1988","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2025.110454_bib9","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ejphar.2011.01.022","article-title":"Evaluation of milnacipran, in comparison with amitriptyline, on cold and mechanical allodynia in a rat model of neuropathic pain","volume":"655","author":"Berrocoso","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110454_bib10","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.physbeh.2015.07.033","article-title":"Depressive-like symptoms in a reserpine-induced model of fibromyalgia in rats","volume":"151","author":"Blasco-Serra","year":"2015","journal-title":"Physiol. Behav."},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110454_bib11","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1017\/S1478951514001059","article-title":"Haloperidol, risperidone, olanzapine and aripiprazole in the management of delirium: a comparison of efficacy, safety, and side effects","volume":"13","author":"Boettger","year":"2015","journal-title":"Palliat. Support Care"},{"key":"10.1016\/j.neuropharm.2025.110454_bib12","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1124\/jpet.108.139410","article-title":"Specific antinociceptive activity of cholest-4-en-3-one, oxime (TRO19622) in experimental models of painful diabetic and chemotherapy-induced neuropathy","volume":"326","author":"Bordet","year":"2008","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110454_bib13","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/0014-2999(88)90107-0","article-title":"Stimulation of dopamine D-2 but not D-1 receptors reduces immobility time of rats in the forced swimming test: implication for antidepressant activity","volume":"148","author":"Borsini","year":"1988","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110454_bib14","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/S1734-1140(11)70605-3","article-title":"Influence of aripiprazole on the antidepressant, anxiolytic and cognitive functions of rats","volume":"63","author":"Burda","year":"2011","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.neuropharm.2025.110454_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/ar2005","article-title":"Biology and therapy of fibromyalgia: genetic aspects of fibromyalgia syndrome","volume":"8","author":"Buskila","year":"2006","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.neuropharm.2025.110454_bib16","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2165\/11597130-000000000-00000","article-title":"The role of antipsychotics in the management of fibromyalgia","volume":"26","author":"Calandre","year":"2012","journal-title":"CNS Drugs"},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110454_bib17","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3109\/00207454.2014.922559","article-title":"Surgical animal models of neuropathic pain: pros and Cons","volume":"125","author":"Challa","year":"2015","journal-title":"Int. J. Neurosci."},{"issue":"12","key":"10.1016\/j.neuropharm.2025.110454_bib18","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.amjmed.2009.09.006","article-title":"Fibromyalgia: an overview","volume":"122","author":"Clauw","year":"2009","journal-title":"Am. J. Med."},{"key":"10.1016\/j.neuropharm.2025.110454_bib19","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1471-4159.2010.06625.x","article-title":"Evidence that pregabalin reduces neuropathic pain by inhibiting the spinal release of glutamate","volume":"113","author":"Coderre","year":"2010","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2025.110454_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.2","article-title":"Neuropathic pain","volume":"3","author":"Colloca","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"8","key":"10.1016\/j.neuropharm.2025.110454_bib21","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1016\/j.cellsig.2012.04.010","article-title":"\u03bc-Opioid and 5-HT1A receptors heterodimerize and show signalling crosstalk via G protein and MAP-kinase pathways","volume":"24","author":"Cussac","year":"2012","journal-title":"Cell. Signal."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110454_bib22","doi-asserted-by":"crossref","first-page":"E09","DOI":"10.1176\/appi.neuropsych.12030069","article-title":"Reversal of aripiprazole-induced tardive akathisia by addition of pregabalin","volume":"25","author":"De Berardis","year":"2013","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110454_bib23","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejphar.2017.06.023","article-title":"Synergic stimulation of serotonin 5-HT1A receptor and \u03b12-adrenoceptors for neuropathic pain relief: preclinical effects of 2-substituted imidazoline derivatives","volume":"810","author":"Di Cesare Mannelli","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110454_bib24","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s40265-017-0700-x","article-title":"Abuse and misuse of pregabalin and gabapentin","volume":"77","author":"Evoy","year":"2017","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110454_bib25","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1177\/2045125312451271","article-title":"Unexpected effect of aripiprazole on nociceptive pain","volume":"2","author":"Fei","year":"2012","journal-title":"Ther Adv Psychopharmacol"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110454_bib26","article-title":"Peripheral antinociception induced by aripiprazole is mediated by the opioid system","volume":"2017","author":"Ferreira","year":"2017","journal-title":"BioMed Res. Int."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110454_bib27","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1037\/a0018647","article-title":"Genetic influences on the dynamics of pain and affect in fibromyalgia","volume":"29","author":"Finan","year":"2010","journal-title":"Health Psychol."},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110454_bib28","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1213\/01.ane.0000287643.13410.5e","article-title":"Pregabalin: its pharmacology and use in pain management","volume":"105","author":"Gajraj","year":"2007","journal-title":"Anesth. Analg."},{"issue":"9","key":"10.1016\/j.neuropharm.2025.110454_bib29","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1358\/mf.2004.26.9.872563","article-title":"Antinociceptive effect of trans-resveratrol in rats: involvement of an opioidergic mechanism","volume":"26","author":"Gupta","year":"2004","journal-title":"Methods Find Exp Clin Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110454_bib30","doi-asserted-by":"crossref","first-page":"911","DOI":"10.2165\/00023210-200721110-00004","article-title":"Adverse effects of atypical antipsychotics: differential risk and clinical implications","volume":"21","author":"Haddad","year":"2007","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neuropharm.2025.110454_bib31","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ejphar.2004.07.024","article-title":"Striatal dopamine D2 receptors in modulation of pain in humans: a review","volume":"500","author":"Hagelberg","year":"2004","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110454_bib32","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.2165\/00003495-200464150-00010","article-title":"Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder","volume":"64","author":"Harrison","year":"2004","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110454_bib33","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1097\/FTD.0b013e3181fc50d5","article-title":"The effect of coadministration of duloxetine on steady-state serum concentration of risperidone and aripiprazole: a study based on therapeutic drug monitoring data","volume":"32","author":"Hendset","year":"2010","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.neuropharm.2025.110454_bib34","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.pain.2010.03.005","article-title":"Upregulations of P2X3 and ASIC3 involve in hyperalgesia induced by cisplatin administration in rats","volume":"149","author":"Hori","year":"2010","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2025.110454_bib35","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/alcalc\/agl037","article-title":"Effects of aripiprazole on alcohol intake in an animal model of high-alcohol drinking","volume":"41","author":"Ingman","year":"2006","journal-title":"Alcohol Alcohol"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110454_bib36","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.neulet.2010.01.010","article-title":"Effects of aripiprazole on MK-801-induced prepulse inhibition deficits and mitogen-activated protein kinase signal transduction pathway","volume":"471","author":"Ishii","year":"2010","journal-title":"Neurosci. Lett."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110454_bib37","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1533-2500.2006.00055.x","article-title":"Pharmacotherapy for neuropathic pain","volume":"6","author":"Jackson","year":"2006","journal-title":"Pain Pract."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110454_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1472-8206.2009.00801.x","article-title":"Animal models of neuropathic pain","volume":"25","author":"Jaggi","year":"2011","journal-title":"Fundam. Clin. Pharmacol."},{"issue":"99","key":"10.1016\/j.neuropharm.2025.110454_bib39","first-page":"209","article-title":"Fibromyalgia, autism, and opioid addiction as natural and induced disorders of the endogenous opioid hormonal system","volume":"18","author":"Johnson","year":"2014","journal-title":"Discov. Med."},{"key":"10.1016\/j.neuropharm.2025.110454_bib40","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0014-2999(02)01532-7","article-title":"The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor","volume":"441","author":"Jordan","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110454_bib41","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1176\/appi.ajp.157.4.514","article-title":"Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia","volume":"157","author":"Kapur","year":"2000","journal-title":"Am. J. Psychiatr."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110454_bib42","article-title":"Four cases of chronic pain that improved dramatically following low-dose aripiprazole administration","volume":"3","author":"Kasahara","year":"2011","journal-title":"Prim Care Companion CNS Disord"},{"key":"10.1016\/j.neuropharm.2025.110454_bib43","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00280-020-04127-8","article-title":"Aripiprazole prevents from development of vincristine-induced neuropathic nociception by limiting neural NOS overexpression and NF-kB hyperactivation","volume":"86","author":"Khalilzadeh","year":"2020","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110454_bib44","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.biopha.2019.01.008","article-title":"Interventional and preventive effects of aripiprazole and ceftriaxone used alone or in combination on oxaliplatin-induced tactile and cold allodynia in mice","volume":"111","author":"Kinga","year":"2019","journal-title":"Biomed. Pharmacother."},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110454_bib45","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0028-3908(01)00100-9","article-title":"Synergistic \u03bc-opioid and 5-HT1A presynaptic inhibition of GABA release in rat periaqueductal gray neurons","volume":"41","author":"Kishimoto","year":"2001","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2025.110454_bib46","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2165\/11539240-000000000-00000","article-title":"Duloxetine: clinical pharmacokinetics and drug interactions","volume":"50","author":"Knadler","year":"2011","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.neuropharm.2025.110454_bib47","doi-asserted-by":"crossref","first-page":"47","DOI":"10.5234\/cnpt.11.47","article-title":"Bell-shaped dose-response curve of antipsychotic drugs and dopaminergic auto-receptors: a hypothesis","volume":"11","author":"Kohno","year":"2020","journal-title":"Clin Neuropsychopharmacol Ther"},{"key":"10.1016\/j.neuropharm.2025.110454_bib48","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.2174\/1570159X17666190430102531","article-title":"Role of descending dopaminergic pathways in pain modulation","volume":"17","author":"Li","year":"2019","journal-title":"Curr. Neuropharmacol."},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110454_bib49","doi-asserted-by":"crossref","first-page":"5981","DOI":"10.3390\/ijms24065981","article-title":"The downregulation of opioid receptors and neuropathic pain","volume":"24","author":"Li","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110454_bib50","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/00207454.2019.1664510","article-title":"Duloxetine for pain in fibromyalgia in adults: a systematic review and a meta-analysis","volume":"130","author":"Lian","year":"2020","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110454_bib51","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2165\/00023210-200418040-00005","article-title":"Dopamine partial agonists: a new class of antipsychotic","volume":"18","author":"Lieberman","year":"2004","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110454_bib52","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/j.pain.0000000000001414","article-title":"Dopamine receptor D2, but not D1, mediates descending dopaminergic pathway-produced analgesic effect in a trigeminal neuropathic pain mouse model","volume":"160","author":"Liu","year":"2019","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2025.110454_bib53","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0165-0327(02)00025-3","article-title":"Altered dopamine D2 receptor function in fibromyalgia patients: a neuroendocrine study with buspirone in women with fibromyalgia compared to female population based controls","volume":"75","author":"Malt","year":"2003","journal-title":"J. Affect. Disord."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110454_bib54","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jpain.2010.07.006","article-title":"Combination drug therapy for chronic pain: a call for more clinical studies","volume":"12","author":"Mao","year":"2011","journal-title":"J. Pain"},{"key":"10.1016\/j.neuropharm.2025.110454_bib55","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.npep.2009.04.001","article-title":"GABA antagonists reverse the somatostatin dependent attenuation of rat locomotor activity","volume":"43","author":"Marazioti","year":"2009","journal-title":"Neuropeptides"},{"key":"10.1016\/j.neuropharm.2025.110454_bib56","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ejphar.2018.07.038","article-title":"Dopaminergic and serotonergic mechanisms in the modulation of pain: in vivo studies in human brain","volume":"834","author":"Martikainen","year":"2018","journal-title":"Eur. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110454_bib57","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/ejp.1328","article-title":"Why mu-opioid agonists have less analgesic efficacy in neuropathic pain?","volume":"23","author":"Mart\u00ednez-Navarro","year":"2019","journal-title":"Eur. J. Pain"},{"key":"10.1016\/j.neuropharm.2025.110454_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2019.172716","article-title":"Spontaneous pain-associated facial expression and efficacy of clinically used drugs in the reserpine-induced rat model of fibromyalgia","volume":"864","author":"Nagakura","year":"2019","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110454_bib59","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.pain.2009.05.024","article-title":"Biogenic amine depletion causes chronic muscular pain and tactile allodynia accompanied by depression: a putative animal model of fibromyalgia","volume":"146","author":"Nagakura","year":"2009","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2025.110454_bib60","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ejphar.2008.10.030","article-title":"Suppression of dopamine-related side effects of morphine by aripiprazole, a dopamine system stabilizer","volume":"600","author":"Narita","year":"2008","journal-title":"Eur. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110454_bib61","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/SPC.0000000000000055","article-title":"Descending pain modulation and chronification of pain","volume":"8","author":"Ossipov","year":"2014","journal-title":"Curr. Opin. Support. Palliat. Care"},{"key":"10.1016\/j.neuropharm.2025.110454_bib62","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.physbeh.2005.08.043","article-title":"Increased sensitivity to the acute effects of MDMA (\u201cecstasy\u201d) in female rats","volume":"86","author":"Palenicek","year":"2005","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.neuropharm.2025.110454_bib63","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1046\/j.1472-8206.2002.00061.x","article-title":"New perspectives in CNS safety pharmacology","volume":"16","author":"Porsolt","year":"2002","journal-title":"Fundam. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110454_bib64","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1358\/dot.2014.50.6.2127023","article-title":"Current status of atypical antipsychotics for the treatment of fibromyalgia","volume":"50","author":"Rico-Villademoros","year":"2014","journal-title":"Drugs Today"},{"issue":"8","key":"10.1016\/j.neuropharm.2025.110454_bib65","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/sj.npp.1300203","article-title":"Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology","volume":"28","author":"Shapiro","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2025.110454_bib66","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.neuropharm.2007.08.013","article-title":"Pregabalin, S-(+)-3-isobutylgaba, activates the descending noradrenergic system to alleviate neuropathic pain in the mouse partial sciatic nerve ligation model","volume":"53","author":"Takeuchi","year":"2007","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2025.110454_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.mehy.2020.109681","article-title":"Is the bell-shaped dose-response curve of the selective serotonin reuptake inhibitor due to 5-HT1A auto-receptors?","volume":"140","author":"Terao","year":"2020","journal-title":"Med. Hypotheses"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110454_bib68","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/240508","article-title":"The anticonvulsant enaminone e139 attenuates paclitaxel-induced neuropathic pain in rodents","volume":"2013","author":"Thangamani","year":"2013","journal-title":"Sci. World J."},{"key":"10.1016\/j.neuropharm.2025.110454_bib69","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0277427","article-title":"The OPRM1 gene and interactions with the 5-HT1a gene regulate conditioned pain modulation in fibromyalgia patients and healthy controls","volume":"17","author":"Tour","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2025.110454_bib70","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1080\/00207454.2019.1638783","article-title":"Investigating the possible pain attenuating mechanisms of pregabalin in chronic constriction injury-induced neuropathic pain in rats","volume":"129","author":"Verma","year":"2019","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110454_bib71","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/bcpt.12036","article-title":"Effects of aripiprazole, an atypical antipsychotic, on the motor alterations induced by acute ethanol administration in mice","volume":"112","author":"Viana","year":"2013","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.neuropharm.2025.110454_bib72","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/00000542-200308000-00028","article-title":"Interaction between the spinal melanocortin and opioid systems in a rat model of neuropathic pain","volume":"99","author":"Vrinten","year":"2003","journal-title":"Anesthesiology (Hagerst.)"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110454_bib73","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/ijcp.12182","article-title":"Pregabalin is increasingly prescribed for neuropathic pain, generalised anxiety disorder and epilepsy but many patients discontinue treatment","volume":"68","author":"Wettermark","year":"2014","journal-title":"Int. J. Clin. Pract."},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110454_bib74","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1586\/eci.10.64","article-title":"Duloxetine for the treatment of fibromyalgia","volume":"6","author":"Wright","year":"2010","journal-title":"Expet Rev. Clin. Immunol."},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110454_bib75","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0197-0186(01)00079-1","article-title":"Tandospirone potentiates the fluoxetine-induced increases in extracellular dopamine via 5-HT1A receptors in the rat medial frontal cortex","volume":"40","author":"Yoshino","year":"2002","journal-title":"Neurochem. Int."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825001601?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825001601?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T08:32:00Z","timestamp":1778142720000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390825001601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":75,"alternative-id":["S0028390825001601"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110454","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aripiprazole: The antiallodynic and antihyperalgesic effects in chronic constriction injury-induced neuropathic pain and reserpine-induced fibromyalgia with possible mechanisms","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110454","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110454"}}